文献速递白血病

三氧化二砷联合全反式维甲酸治疗高危急性早幼粒细胞白血病:APOLLO试验结果

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.
PubMed 文献 · J Clin Oncol · 2025-08-18

APOLLO是一项III期前瞻性试验,比较三氧化二砷(ATO)联合全反式维甲酸(ATRA)加低剂量去甲氧柔红霉素方案与标准ATRA加蒽环类化疗方案治疗高危急性早幼粒细胞白血病(APL)的疗效。结果显示,ATRA-ATO组2年无事件生存(EFS)为88%,ATRA-CHT组为71%(HR 0.4,95%CI 0.17-0.92,P=0.02);ATRA-ATO组分子学复发1例(1.5%),ATRA-CHT组8例(12.3%)(P=0.014)。结论支持ATO联合ATRA用于新诊断高危APL患者。

要点

  • ATRA-ATO组2年EFS为88%,ATRA-CHT组为71%(HR 0.4,95%CI 0.17-0.92,P=0.02)。
  • ATRA-ATO组分子学复发1例(1.5%),ATRA-CHT组8例(12.3%)(P=0.014)。
  • ATRA-ATO组严重治疗出现的不良事件报告率为32%,ATRA-CHT组为68%(P<0.01)。

核心结论

  • APOLLO试验结果支持使用三氧化二砷(ATO)联合全反式维甲酸(ATRA)治疗新诊断的高危急性早幼粒细胞白血病(APL)患者。

研究设计与样本

  • III期APOLLO试验前瞻性比较ATRA-ATO方案(ATO 0.15 mg/kg每日一次和ATRA 45 mg/m2每日两次,直至完全缓解,第1天和第3天给予去甲氧柔红霉素12 mg/m2两次,随后四个ATRA-ATO巩固周期)与ATRA-CHT方案(ATRA 45 mg/m2每日两次和去甲氧柔红霉素12 mg/m2每日一次,第1、3、5、7天,随后三个化疗巩固周期和2年维持治疗)在成人新诊断高危APL患者中的疗效;主要终点为2年无事件生存(EFS)。
  • 截至2022年7月,133例合格患者接受ATRA-ATO(n=68)或ATRA-CHT(n=65);研究因COVID-19大流行期间入组缓慢而提前终止;中位随访37个月(范围1.7-88.6个月)。

主要发现

  • 2年EFS在ATRA-ATO组为88%,在ATRA-CHT组为71%(HR 0.4,95%CI 0.17-0.92;log-rank检验P=0.02)。
  • 从完全缓解起中位7.8个月和12.1个月时,分子学复发在ATRA-ATO组为1例(1.5%),在ATRA-CHT组为8例(12.3%)(P=0.014)。
  • 报告严重治疗出现的不良事件的患者比例在ATRA-ATO组为32%,在ATRA-CHT组为68%(P<0.01)。

关键数值与推荐

  • ATRA-ATO方案:ATO 0.15 mg/kg每日一次和ATRA 45 mg/m2每日两次,直至完全缓解,第1天和第3天给予去甲氧柔红霉素12 mg/m2两次,随后四个ATRA-ATO巩固周期。
  • ATRA-CHT方案:ATRA 45 mg/m2每日两次和去甲氧柔红霉素12 mg/m2每日一次,第1、3、5、7天,随后三个化疗巩固周期和2年维持治疗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 研究因COVID-19大流行期间入组缓慢而提前终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140). METHODS: Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m2 twice daily and idarubicin 12 mg/m2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS: As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients (P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events (P < .01). CONCLUSION: The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Platzbecker U, Adès L, Montesinos P, et al. Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. J Clin Oncol. 2025. PMID: 40825164. doi:10.1200/JCO-25-00535

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。